Effectiveness of switching strategies in <scp>CGRP</scp> monoclonal antibody therapy for migraine: A retrospective cohort study
Switching between anti-CGRP mAbs resulted in a reduction in MHDs, with no significant differences based on the mechanism of action. Factors such as the number of doses of the first mAb and the inter-treatment interval did not appear to predict a ≥50% reduction in MHDs at month 3. Our findings support the viability of switching as an effective treatment option for patients with migraine who do not respond to initial mAb therapy.
Authors
- Alex Jaimes (ORCID: https://orcid.org/0000-0002-0890-9484)
- Olga Pajares
- Andrea Gómez
- Jaime Rodríguez‐Vico
Institutions
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1111/head.14865
- Citations
- 10
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.86
Funders
- Eli Lilly and Company
- Teva Pharmaceutical Industries
- Allergan